Alfasigma S.p.A.

The sponsor maintains an active research programme in pediatric rheumatology, with particular emphasis on juvenile idiopathic arthritis and its various manifestations. Research efforts concentrate on understanding disease mechanisms in children and adolescents, exploring therapeutic interventions specifically designed for younger patient populations. The programme includes investigations into polyarticular-course juvenile idiopathic arthritis, addressing the unique challenges of managing chronic inflammatory joint conditions in developing patients.

• Pharmacokinetic characterization in pediatric populations
• Safety and tolerability assessment in children and adolescents
• Long-term extension studies in juvenile arthritis
• Treatment efficacy evaluation in polyarticular disease

The research extends to evaluating treatment responses across different age groups within the pediatric spectrum, from school-age children through adolescence, ensuring comprehensive understanding of therapeutic profiles in growing patients.